	US 11,891,348 B2
	Cycloheptylamine derivatives as anti-diabetic agents
Abdu Adem, Al Ain (AE); Shaikha S. Al Neyadi, Al Ain (AE); Ibrahim M. Abdou, Al Ain (AE); Alaa A. Salem, Al Ain (AE); and Naheed Amir, Al Ain (AE)
Assigned to UNITED ARAB EMIRATES UNIVERSITY, Al Ain (AE)
Filed by UNITED ARAB EMIRATES UNIVERSITY, Al Ain (AE)
Filed on Jul. 27, 2021, as Appl. No. 17/386,337.
Application 17/386,337 is a division of application No. 16/866,856, filed on May 5, 2020, granted, now 11,091,426.
Prior Publication US 2021/0347725 A1, Nov. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/48 (2006.01); C07D 401/04 (2006.01); C07C 279/16 (2006.01); C07C 211/35 (2006.01); C07C 317/42 (2006.01); C07C 279/26 (2006.01)

CPC C07C 211/35 (2013.01) [C07C 279/16 (2013.01); C07C 279/26 (2013.01); C07C 317/42 (2013.01); C07D 239/48 (2013.01); C07D 401/04 (2013.01)]

3 Claims

1. Cycloalkylamine derivatives, comprising compounds selected from groups consisting of cycloheptylamine hydrochloride, cycloheptylamine hydrobromide, cyclopentylamine hydrochloride, 1-cycloheptyl-[4,4′-bipyridin]-1-ium chloride, cyclohexylamine hydrochloride N1,N2-dicycloheptyloxalamide, 1-[3′,5′-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1′-(4″-methyl-1″,3″-phenylene)bis(3-cycloheptylurea), 1-(2′-aminopyrimidin-4′-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3′-cycloheptylureido)-N-(5″-methylisoxazol-3″-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.